ArticleVaccine2023
Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.
Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.Pathogens (Basel, Switzerland) · 2024Pooled it
- Pooled it
- Complete genome sequences of eight poliovirus Sabin 2-derived and five novel oral poliovirus 2-derived circulating vaccine-derived poliovirus (CVDPV) genomes with single-end recombination from Botswana, 2022-2023.Microbiology resource announcements · 2026Article
- Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda.Nature microbiology · 2026Article
- Co-Administration of Novel Oral Polio Vaccine Type 2 and Bivalent Oral Polio Vaccine: Current Evidence, Challenges, and Implications for the Polio Eradication Endgame.Infection and drug resistance · 2026Review
- Editorial: Eradicating polio in Pakistan and other countries in the Eastern Mediterranean region: epidemiology, surveillance, and immunization.Frontiers in public health · 2026Article
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Population immunity to the three serotypes of poliovirus post-interruption of wild poliovirus transmission in Nigeria.Journal of virus eradication · 2025Article
- Historical and current spatiotemporal patterns of wild and vaccine-derived poliovirus spread.Nature microbiology · 2025Article
- Impediments to Progress Toward Polio Eradication During 2014-2024: Effectively Addressing the Current Challenges.Vaccines · 2025Review
- Safety of nOPV2 administered during a supplementary immunisation activity in Uganda, 2022: data triangulation from a prospective cohort event monitoring programme and vaccine safety surveillance reports.The Lancet. Global health · 2025Article
- Immunization safety monitoring: addressing vaccine hesitancy and enhancing coverage in crisis-affected regions-insights from Lebanon, Ukraine, and Sudan.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Complete genome sequences of nine double recombinant vaccine-derived novel oral poliovirus type 2 genomes from Nigeria 2023-2024.Microbiology resource announcements · 2024Article
- Monitoring the Risk of Type-2 Circulating Vaccine-Derived Poliovirus Emergence During Roll-Out of Type-2 Novel Oral Polio Vaccine.Vaccines · 2024Article
- Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2023-June 2024.MMWR. Morbidity and mortality weekly report · 2024Article
- Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).Pathogens (Basel, Switzerland) · 2024Article
- Identifying and reducing risks of neurological complications associated with vaccination.Nature reviews. Neurology · 2024Review
- Article
- Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023.MMWR. Morbidity and mortality weekly report · 2024Article
- The Last Mile in Polio Eradication: Program Challenges and Perseverance.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
Abstract
To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response - novel oral polio vaccine type 2 (nOPV2). The World Health Organization's (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for nOPV2 on 13 November 2020. The WHO's EUL procedure was created to assess and list unlicensed vaccines, therapeutics and diagnostics to enable their use in response to a Public Health Emergency of International Concern (PHEIC). nOPV2 was the first vaccine to receive an EUL, paving the way for other emergency vaccines. In this report, we summarise the pathway for nOPV2 roll-out under EUL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.